REVIEW PAPER
Quality of life in patients with gastroesophageal reflux disease following pharmacotherapeutic, endoscopic, and surgical treatment
1
Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Clinical Hospital, Bialystok, Poland
2
Department of Clinical Medicine, Medical University of Bialystok, Bialystok, Poland
3
Department of Nursing Surgery, Medical University of Bialystok, Bialystok, Poland
Submission date: 2016-10-04
Acceptance date: 2016-12-05
Publication date: 2016-12-28
Medical Studies 2016;32(4):299-306
KEYWORDS
TOPICS
ABSTRACT
Gastroesophageal reflux disease (GERD) is associated with bothersome symptoms. Their chronic and recurrent character has a negative impact on the physical and mental status of the patients. Improvement in health-related quality of life (HRQOL) of GERD patients along with decreasing the severity of symptoms remain the main aims of therapy. This paper reviews literature regarding HRQOL in GERD patients, as well as the impact of various treatment modalities on the patient’s status, the incidence and severity of symptoms thereof, and subjective quality of life. Additionally, the factors that may influence the treatment outcome are also discussed. Several studies showed that the improvement of HRQOL is greater after surgical treatment than with pharmacological therapy. However, long-term studies are still needed to determine if surgery can constitute the equivalent of lifelong medical therapy.
REFERENCES (54)
1.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2.
Sawaya RA, Macgill A, Parkman HP, Friedenberg FK. Use of the Montreal global definition as an assessment of quality of life in reflux disease. Dis Esophagus 2012; 25: 477-483.
3.
Katz PO. Gastroesophageal reflux disease: state of the art. Rev Gastroenterol Disord 2001; 1: 128-38.
4.
Nowak A, Marek T, Rydzewska G, Paradowski L, Chojnicki J, Wallner G, Poniewierka E, Wróblewski T. Wytyczne Polskiego Towarzystwa Gastroenterologii. Choroba refluksowa przełyku. Gastroenterol Pol 2005; 12: 313-9.
5.
Tobiasz-Adamczyk B. Geneza zdrowia, koncepcje i ewolucja pojęcia jakości życia. In: Jakość życia w chorobach układu sercowo-naczyniowego. Kawecka-Jaszcz K, Klocek M, Tobiasz-Adamczyk B (eds.). Termedia, Poznan 2006; 9-42.
6.
Brzyski P. Trafność i rzetelność skal pomiarowych. In: Jakość życia w chorobach układu sercowo-naczyniowego. Kawecka-Jaszcz K, Klocek M, Tobiasz-Adamczyk B (eds.). Termedia, Poznan 2006; 43-54.
7.
Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut 2004; 53 Suppl 4: iv35-9.
8.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
9.
Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437-40.
10.
Przytulski K. Jakość życia w chorobie refluksowej. Gastroenterol Pol 2004; 11: 559-63.
11.
Chan Y, Ching JY, Cheung CM, Tsoi KK, Polder-Verkiel S,Pang SH, Quan WL, Kee KM, Chan FK, Sung JJ, Wu JC. Development and validation of a disease-specific quality of life questionnaire for gastro-oesophageal reflux disease: the GERD-QOL questionnaire. Aliment Pharmacol Ther 2010; 31: 452-60.
12.
Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-8.
13.
Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767-76.
14.
Pace F, Negrini C, Wiklund I, Rossi C, Savarino V; Italian One Investigators Study Group. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22: 349-56.
15.
Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further vali-dation of the Los Angeles classification. Gut 1999; 45: 172-80.
16.
Pehlivanov ND, Olyaee M, Sarosiek I, McCallum RW. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003; 18: 883-90.
17.
Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Sved-lund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-52.
18.
Glise H, Hallerback B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol 1996; 221: 14-7.
19.
Tsuzuki T, Okada H, Kawahara Y, Takenaka R, Nasu J, Ishioka H, Fujiwara A, Yoshinaga F, Yamamoto K. Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol 2011; 17: 1480-7.
20.
Chen M, Xiong L, Chen H, Xu A, He L, Hu P. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol 2005; 40: 759-67.
21.
Eslick GD, Talley NJ. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life – a population-based study. J Clin Gastroenterol 2009; 43: 111-7.
22.
Reguła J, Kulich KR, Stasiewicz J, Jasiński B, Carlsson J, Wiklund I. Obciążenie polskich pacjentów związane z chorobą refluksową przełyku. Przegl Epidemiol 2005; 59: 75-85.
23.
Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96 (8 Suppl): S46-53.
24.
Quigley EM. Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (3 Suppl): S24-30.
25.
Tytgat GN. Review article: treatment of mild and severe cases of GERD. Aliment Pharmacol Ther 2002; 16 (Suppl 4): S73-8.
26.
Contini S, Bertele A, Nervi G, Zinicola R, Scarpignato C. Quality of life for patients with gastroesophageal reflux disease 2 years after laparoscopic fundoplication. Evaluation of the results obtained during the initial experience. Surg Endosc 2002; 16: 1555-60.
27.
Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008; 27: 960-70.
28.
Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther 2012; 35: 1257-66.
29.
Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instrument. Am J Gastroenterol 2001; 96: 1998-2004.
30.
Carrau RL, Khidr A, Crawley JA, Hillson EM, Davis JK, Pashos CL. The impact of laryngopharyngeal reflux on patient-reported quality of life. Laryngoscope 2004; 114: 670-4.
31.
Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7: 372-8.
32.
Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberöd A, Anker-Hansen O. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94: 1782-9.
33.
Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803-9.
34.
Wiklund I, Hansen A, Bergheim R, Moum B. Esomeprazole is superior to ranitidine 150 mg bid in maintaining quality of life (QoL) in patients with symptomatic GERD. Scand J Gastroenterol 2003; 38: 22.
35.
Kovacs TO, Freston JW, Haber MM, Atkinson S, Hunt B,Peura DA. Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. Dig Dis Sci 2010; 55: 1325-36.
36.
Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Romàn J, Walan A; Long-Term Study Group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
37.
Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. World J Gastroenterol 2012; 18: 2390-5.
38.
Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
39.
Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 1999; 34: 337-40.
40.
Hongo M, Miwa H, Kusano M, group JF. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors. J Gastroenterol Hepatol 2012; 27: 913-8.
41.
Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 618-27.
42.
Aanen MC, Weusten BL, Numans ME, de Wit NJ, Samsom M, Smout AJ. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association. J Clin Gastroenterol 2008; 42: 441-7.
43.
Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engström C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A; Nordic GERD Study Group. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009; 7: 1292-8.
44.
Wileman SM, McCann S, Grant AM, Krukowski ZH, Bruce J. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2010; 3: CD003243.
45.
Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, Goldsmith C. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. Surg Endosc 2011; 25: 2547-54.
46.
Wileman SM. ACP Journal Club: laparoscopic fundoplication is better than medical management for some quality-of-life measures in GERD. Ann Intern Med 2010; 153: JC3-10.
47.
Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Långström G, Lind T, Lundell L; LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969-77.
48.
Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, Thursz M, Russell I, Campbell M; REFLUX Trial Group. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease – a UK collaborative study. The REFLUX trial. Health Technol Assess 2008; 12: 1-181.
49.
Kamolz T, Granderath FA, Bammer T, Pasiut M, Pointner R. Dysphagia and quality of life after laparoscopic Nissen fundoplication in patients with and without prosthetic reinforcement of the hiatal crura. Surg Endosc 2002; 16: 572-7.
50.
Aziz EM, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, Guda MF, Lehman GA. A prospective randomized trail of sham, single-dose Stretta, and duble-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc 2010; 24: 818-25.
51.
Dughera L, Navino M, Cassolino P, De Cento M, Cacciotella L, Cisarò F, Chiaverina M. Long-term results of radiofrequency energy delivery for the treatment of GERD: results of a prospective 48-month study. Diagn Ther Endosc 2011; 2011: 507157.
52.
Perry KA, Banerjee A, Melvin WS. Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 2012; 22: 283-8.
53.
Pleskow D, Rothstein R, Kozarek R, Haber G, Gostout C, Lembo A. Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. Surg Endosc 2007; 21: 439-44.
54.
Antoniou SA, Koch OO, Kaindlstorfer A, Asche KU, Berger J, Granderath FA, Pointner R. Endoscopic full-thickness plication versus laparoscopic fundoplication: a prospective study on quality of life and symptom control. Surg Endosc 2012; 26: 1063-8.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
